Log In
BCIQ
Print this Print this
 

Vaniqa, eflornithine

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionOrnithine decarboxylase inhibitor
Molecular Target Decarboxylase
Mechanism of ActionDecarboxylase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHair removal
Indication DetailsReduce unwanted facial hair in women
Regulatory Designation
PartnerAlmirall S.A.;
Cipher Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$0.4M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/06/2015

Undisclosed

$0.4M

Undisclosed

Get a free BioCentury trial today